Skip to content

Study · Animal study (in vivo) · rat · 1986

6 results

Oxytocin and [1-deamino, 8-D-arginine]-vasopressin (dDAVP): intrathecal effects on blood pressure, heart rate and urine output.

Riphagen CL, Pittman QJ

Brain research1 May 1986Cited by 21 (Europe PMC)

PMID3755073 (opens in a new tab)DOI10.1016/0006-8993(86)90432-4 (opens in a new tab)PepBankPUB-03755073
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Activity measurement

    In rats, intrathecal desmopressin was less potent than AVP in changing cardiovascular function.

    In plain wordsIn rats, intrathecal desmopressin changed cardiovascular function less potently than AVP.

    Peptide
    Desmopressin
    Outcome
    Not applicableCardiovascular function
    Study

    ratn: not reported in source

    Intrathecal administration
    Comparator
    AVP
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · intrathecalAs given in this study (rat).

    Source sentences

    Summary
    Neither oxytocin (OXT) nor [1-deamino, 8-D-arginine]-vasopressin (dDAVP) were as potent as AVP in inducing changes in cardiovascular function and renal output.
    1 context sentence
    Summary · context
    Two analogues of arginine vasopressin (AVP) were administered intrathecally in rats.
  2. 02AnimalAnimal study (in vivo)Activity measurement

    In rats, intrathecal desmopressin was less potent than AVP in changing renal output.

    In plain wordsIn rats, intrathecal desmopressin changed renal output less potently than AVP.

    Peptide
    Desmopressin
    Outcome
    Not applicableRenal output
    Study

    ratn: not reported in source

    Intrathecal administration
    Comparator
    AVP
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · intrathecalAs given in this study (rat).

    Source sentences

    Summary
    Neither oxytocin (OXT) nor [1-deamino, 8-D-arginine]-vasopressin (dDAVP) were as potent as AVP in inducing changes in cardiovascular function and renal output.
    1 context sentence
    Summary · context
    Two analogues of arginine vasopressin (AVP) were administered intrathecally in rats.
  3. 03AnimalAnimal study (in vivo)Activity measurement

    In rats, intrathecal oxytocin was less potent than AVP in changing cardiovascular function.

    In plain wordsIn rats, intrathecal oxytocin changed cardiovascular function less potently than AVP.

    Peptide
    Oxytocin
    Outcome
    Not applicableCardiovascular function
    Study

    ratn: not reported in source

    Intrathecal administration
    Comparator
    AVP
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · intrathecalAs given in this study (rat).

    Source sentences

    Summary
    Neither oxytocin (OXT) nor [1-deamino, 8-D-arginine]-vasopressin (dDAVP) were as potent as AVP in inducing changes in cardiovascular function and renal output.
    1 context sentence
    Summary · context
    Two analogues of arginine vasopressin (AVP) were administered intrathecally in rats.
  4. 04AnimalAnimal study (in vivo)Activity measurement

    In rats, intrathecal oxytocin was less potent than AVP in changing renal output.

    In plain wordsIn rats, intrathecal oxytocin changed renal output less potently than AVP.

    Peptide
    Oxytocin
    Outcome
    Not applicableRenal output
    Study

    ratn: not reported in source

    Intrathecal administration
    Comparator
    AVP
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · intrathecalAs given in this study (rat).

    Source sentences

    Summary
    Neither oxytocin (OXT) nor [1-deamino, 8-D-arginine]-vasopressin (dDAVP) were as potent as AVP in inducing changes in cardiovascular function and renal output.
    1 context sentence
    Summary · context
    Two analogues of arginine vasopressin (AVP) were administered intrathecally in rats.
  5. 05AnimalAnimal study (in vivo)Activity measurement

    In rats, large intrathecal oxytocin doses significantly changed pressor responses.

    In plain wordsIn rats, large intrathecal oxytocin doses changed pressor responses.

    Peptide
    Oxytocin
    Outcome
    Direction not reportedPressor response
    Study

    ratn: not reported in source

    Intrathecal administration
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Large doses · intrathecalAs given in this study (rat).

    Source sentences

    Summary
    Large doses of OXT, however, did cause significant changes in pressor responses and urine output, suggesting that this peptide may act at spinal levels, possibly as a weak agonist on AVP receptors.
    1 context sentence
    Summary · context
    Two analogues of arginine vasopressin (AVP) were administered intrathecally in rats.
  6. 06AnimalAnimal study (in vivo)Activity measurement

    In rats, large intrathecal oxytocin doses significantly changed urine output.

    In plain wordsIn rats, large intrathecal oxytocin doses changed urine output.

    Peptide
    Oxytocin
    Outcome
    Direction not reportedUrine output
    Study

    ratn: not reported in source

    Intrathecal administration
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Large doses · intrathecalAs given in this study (rat).

    Source sentences

    Summary
    Large doses of OXT, however, did cause significant changes in pressor responses and urine output, suggesting that this peptide may act at spinal levels, possibly as a weak agonist on AVP receptors.
    1 context sentence
    Summary · context
    Two analogues of arginine vasopressin (AVP) were administered intrathecally in rats.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:35 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:53 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.